Sepsis-Associated Purpura Fulminans International Registry - Europe
Kata kunci
Abstrak
Deskripsi
Purpura fulminans is the clinical manifestation of disseminated thrombosis in dermal and systemic microcirculation. This rare disease is frequently associated with multiple organ failure and represents a life-threatening condition with mortality exceeding 50 %. In the vast proportion of cases, the condition has been shown to emerge secondary to acquired Protein C deficiency associated with severe sepsis, mostly of meningococcal or pneumococcal origin.
A consistent therapeutic approach to sepsis-associated Purpura fulminans (SAPF) has not been established yet. With exaggerated pro-coagulant activity being confirmed as the key pathogenic aspect, several treatment modalities aiming at the balance restoration in the coagulation cascade have been considered.
SAPF causality might have been substantially altered in the wake of widespread meningococcal and pneumococcal vaccination. There are neither evidence-based treatment guidelines nor comparative evaluation of the efficacy of different therapeutic approaches.
The present registry aims at a) large-scale data accumulation and comprehensive evaluation of the incidence, causality and current treatment strategies of SAPF, b) comparative assessment of treatment strategies including or not including protein C supplementation c) identification of patient subgroups of particular eligibility for Protein C treatment, as judged by established criteria of disease severity assessment, d) feedback of aggregated data to registry contributors, thus permitting quality management and standard updates, e) dissemination of data evaluation summaries and recommendations for the use of Protein C formulations in clinical routine, f) elaboration of a framework for SAPF treatment recommendations and guidelines.
The registry comprises prospective, multicentric open-label data collection on the current state of incidence and management of SAPF, regardless of the etiopathogenic background. It will include comprehensive records on diagnosis, morbidity and management of SAPF, supplied in the form of electronic case report forms (eCRFs) by the participating centers over a period of three years.
tanggal
Terakhir Diverifikasi: | 01/31/2019 |
Pertama Dikirim: | 09/09/2014 |
Perkiraan Pendaftaran Telah Dikirim: | 09/09/2014 |
Pertama Diposting: | 09/11/2014 |
Pembaruan Terakhir Dikirim: | 04/07/2019 |
Pembaruan Terakhir Diposting: | 04/09/2019 |
Tanggal Mulai Studi Sebenarnya: | 03/31/2016 |
Perkiraan Tanggal Penyelesaian Utama: | 11/30/2019 |
Perkiraan Tanggal Penyelesaian Studi: | 02/29/2020 |
Kondisi atau penyakit
Tahap
Kelompok Lengan
Lengan | Intervensi / pengobatan |
---|---|
Purpura fulminans Patients diagnosed with Purpura fulminans in association with sepsis |
Kriteria kelayakan
Jenis Kelamin yang Layak untuk Belajar | All |
Metode pengambilan sampel | Non-Probability Sample |
Menerima Relawan Sehat | Iya |
Kriteria | Inclusion Criteria: - Diagnosis of sepsis and Purpura fulminans - Signed informed consent Exclusion Criteria: - Premature neonates (below gestational age of 36 weeks) |
Hasil
Ukuran Hasil Utama
1. Mortality [during hospital stay (estimated up to 3 months)]
Ukuran Hasil Sekunder
1. Morbidity [7 days]
2. Extent and severity of Purpura fulminans lesions [7 days]
3. Purpura fulminans related surgery [during hospital stay (estimated up to 3 months)]
4. Invasive pathogen [during hospital stay (estimated up to 3 months)]
5. Site of primary infection [during hospital stay (estimated up to 3 months)]
6. Duration of ICU stay [during ICU stay (estimated up to 3 months)]
7. Duration of hospital stay [during hospital stay (estimated up to 3 months)]
8. Laboratory indices of organ dysfunction [7 days]
9. Inflammatory parameters [7 days]
10. Coagulation parameters [7 days]
11. Hematological parameters [7 days]
12. Adverse drug reactions [during hospital stay (estimated up to 3 months)]
Ukuran Hasil Lainnya
1. Antimicrobial therapy [during ICU stay (estimated up to 3 months)]
2. Vasopressors [during ICU stay (estimated up to 3 months)]
3. Blood products [during ICU stay (estimated up to 3 months)]
4. Anticoagulant treatment [during ICU stay (estimated up to 3 months)]
5. Adjunctive therapy [7 days]
6. Duration of mechanical ventilation [during ICU stay (estimated up to 3 months)]
7. Need of renal replacement therapy [during ICU stay (estimated up to 3 months)]
8. ECMO or other circulatory support systems [during ICU stay (estimated up to 3 months)]